Recently, tafasitamab in combination with lenalidomide has received approval by the FDA for the treatment of adult patients with relapsed or refractory DLBCL, making the antibody the fourth clinically approved Fc engineered antibody optimized for enhanced FcγR binding in oncology next to mogamulizumab, obinutuzumab and Belantamab–Mafodotin, which bind the CC chemokine receptor 4, CD20 and B cell maturation antigen (BCMA), respectively [32]. Here, TNFRSF17 is linked to diffuse large B-cell lymphoma.